What happens when you stop Weight-Loss shots? new study tests backup plans

NCT ID NCT06605703

Completed Disease control Sponsor: WW International Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 226 adults who had lost at least 15% of their body weight while taking GLP-1 medications like Wegovy or Ozempic. Participants stopped their GLP-1 drug and were given either bupropion-naltrexone or bupropion-naltrexone-metformin, plus behavioral support through a telehealth platform. The main goal was to see how much weight they regained or lost after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bupropion-Naltrexone and Bupropion-Naltrexone-Metformin
What this could lead to: If successful, this could point toward effective options to maintain weight loss after stopping popular GLP-1 medications like Wegovy or Ozempic.
What could go wrong: This is a small, 12-week completed trial with 226 participants, so results may not apply to everyone. The step-down drugs have their own side effects and may not fully prevent weight regain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

WW International, Inc

New York, New York, 10011, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.